Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DEFENSE HEALTH AGENCY (DHA)
Contract Value
Not provided
Codes & Classification
Solicitation Number
HT9402-26-Q-9201
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents5
The Department of Defense (DoD), through the Defense Health Agency (DHA), has issued a solicitation (Procurement Identifier: HT9402-26-Q-9201) seeking quotations for pharmaceutical agents as part of its ongoing commitment to maintaining an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). This procurement is mandated by 10 U.S.C. § 1074g and governed by implementing regulations at 32 CFR Section 199.21, which require the DoD Pharmacy and Therapeutics (P&T) Committee to evaluate the clinical and cost effectiveness of pharmaceutical agents for inclusion in the DoD Uniform Formulary (UF).
The primary objective of this solicitation is to establish Uniform Formulary Blanket Purchase Agreements (UF BPAs) and Uniform Formulary Additional Discount Program Agreements (UF ADPs) with qualified pharmaceutical manufacturers or suppliers. These agreements will support the DoD’s pharmacy program by ensuring access to clinically effective and cost-efficient medications for service members, retirees, and their families.
For the May 2026 P&T Committee meeting, the following drug classes and specific agents are under review for potential placement on the Uniform Formulary:
a. Antihemophilic Agents - Non-Factor Agents:
- ALHEMO PEN
- HEMLIBRA
- HYMPAVZI PEN
- QFITLIA
b. Leukemia and Lymphoma - BCR-ABL-TKI:
- BOSULIF
- DANZITEN
- ICLUSIG
- IMKELDI
- PHYRAGO
- SCEMBLIX
- SPRYCEL
- TASIGNA
- NILOTINIB TARTRATE
The solicitation package, including the RFQ and appendices for both the UF BPA and UF ADP, provides detailed instructions, requirements, and important deadlines. Prospective offerors are encouraged to review these documents thoroughly to ensure compliance with submission requirements. A pre-quotation teleconference is scheduled for February 11, 2026, with details outlined in Part 2.4 of the RFQ, offering an opportunity for interested parties to seek clarification and guidance prior to submitting their quotations.
Key requirements for this procurement include the provision of pharmaceutical agents within the specified drug classes, adherence to the DoD’s formulary placement process, and the ability to offer competitive pricing and additional discounts as applicable. The expected deliverables are the timely and reliable supply of the selected pharmaceutical agents under the terms of the awarded agreements.
This opportunity is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing, 2022 version) and Product Service Code 6505 (Drugs and Biologicals). There are no set-aside restrictions; the solicitation is open to all qualified entities. The place of performance is San Antonio, Texas, United States.
The contracting activity is managed by the Defense Health Agency (DHA), a federal office under the Department of Defense. The primary point of contact for this solicitation is Tracy Banks ([email protected]), with Kirk Heyen ([email protected]) listed as the secondary contact.
Interested contractors should note the active status of this notice and the response deadline of February 4, 2026, at 17:04. All relevant documents and attachments are available via the official SAM.gov opportunity listing (Opportunity ID: fe66d512d41448bb81e795cdc32fc134).
This procurement represents a significant opportunity for pharmaceutical manufacturers and suppliers with capabilities in the specified therapeutic areas to partner with the DoD in supporting the health and readiness of military personnel and their families. Contractors are advised to carefully review the RFQ and associated materials to ensure alignment with the program’s objectives and compliance with all submission requirements.